

FOR IMMEDIATE RELEASE
TSX VENTURE: HTL



**HAMILTON THORNE TO PRESENT AT THE 2015
LD MICRO MAIN EVENT**

BEVERLY, MA and TORONTO, Ontario – November 23, 2015 – Hamilton Thorne Ltd. (TSX-V: HTL), a leading provider of precision laser devices and advanced image analysis systems for the fertility, stem cell and developmental biology research markets, today announced that David Wolf, President and CEO of Hamilton Thorne will be presenting at the LD Micro Main Event (www.ldmicro.com), on Wednesday, December 2 at 5:00 pm Pacific Time (8:00 pm Eastern Time), at the Luxe Sunset Bel Air Hotel in Los Angeles, CA.

Mr. Wolf will be available for one-on-one meetings with the investment community on December 2 and 3. Investors attending the conference who wish to schedule a meeting should notify their LD Micro conference contact or Hamilton Thorne at ir@hamiltonthorne.com.

The LD Micro Main Event is in its 8th year and will feature 210 companies in the small / micro-cap space.

About Hamilton Thorne Ltd. (www.hamiltonthorne.com)

Hamilton Thorne designs, manufactures and distributes precision laser devices and advanced imaging systems for the fertility, stem cell and developmental biology research markets. It provides novel solutions for Life Science that reduce cost, increase productivity, improve results and enable research breakthroughs in fertility, regenerative medicine, and stem cell research markets. Hamilton Thorne's laser products attach to standard inverted microscopes and operate as micro-surgical instruments, enabling a wide array of scientific applications and IVF procedures. Its imaging systems improve outcomes in human IVF clinics and animal breeding facilities and provide high-end toxicology analyses.

Hamilton Thorne's growing customer base includes pharmaceutical companies, biotechnology companies, fertility clinics, university research centers, and other commercial and academic research establishments worldwide. Current customers include world-leading research labs such as Harvard, MIT, Yale, McGill, DuPont, Monsanto, Charles River Labs, Jackson Labs, Merck, Novartis, Pfizer, and Oxford and Cambridge.

Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.

Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available at www.sedar.com.

For more information, please contact:

David Wolf, President & CEO
Hamilton Thorne Ltd.
978-921-2050
ir@hamiltonthorne.com

Michael Bruns, CFO
Hamilton Thorne Ltd.
978-921-2050
ir@hamiltonthorne.com